Skip to content
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
SideMenu
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
May 2, 2022
AAM
Generics Drive Savings Yet Patients Continue to Pay More
Blog
April 19, 2022
AAM
As Health Care Spending in US Projected to Increase, Generics and Biosimilars Expected to Moderate Growth
Blog
April 19, 2022
AAM
Challenges & Solutions for Prescription Drug Savings Identified by MedPAC
Blog
April 8, 2022
AAM
HHS OIG Report Demonstrates Need for Changes to Part D to Increase Biosimilar Use
Blog
March 30, 2022
AAM
KC is Enjoying Life— “a Pretty Good Deal” on Prescriptions
Blog
March 24, 2022
AAM
The Savings Add Up for Patients
Blog
March 23, 2022
AAM
Greg is Treating His Ulcerative Colitis, and Enjoying a Slice or Two
Blog
March 18, 2022
AAM
Senate Finance Hearing Highlights Ways to Reduce Drug Prices without Harming Patients
Blog
March 15, 2022
AAM
Eileen is Singing, Dancing and Taking Care of Herself with Biosimilars
Blog
March 7, 2022
AAM
Women’s History Month: Honoring Yesterday’s and Today’s Leaders
Blog
February 23, 2022
AAM
Access! 2022: Recapping AAM’s Annual Meeting
Blog
February 16, 2022
AAM
Black History Month: 10 Pioneers to Celebrate
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
